Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Michael

Showing results (1001-1010 of 1,111) with videos related to

Pageof 112
Sort By:
Nature Medicine|June 13, 2018
Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infectionDonn J Colby, Lydie Trautmann, Suteeraporn Pinyakorn, et al.
Science Translational Medicine|December 15, 2017
Durability and correlates of vaccine protection against Zika virus in rhesus monkeysPeter Abbink, Rafael A Larocca, Kittipos Visitsunthorn, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 15, 2019
Terminal Effector CD8 T Cells Defined by an IKZF2<sup>+</sup>IL-7R<sup>-</sup> Transcriptional Signature Express FcγRIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular CytotoxicityProssy Naluyima, Kerri G Lal, Margaret C Costanzo, et al.
The Journal of Infectious Diseases|July 28, 2012
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/ESupachai Rerks-Ngarm, Robert M Paris, Supamit Chunsutthiwat, et al.
The Lancet. HIV|February 10, 2020
Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trialPunnee Pitisuttithum, Sorachai Nitayaphan, Suwat Chariyalertsak, et al.
Plos One|May 12, 2017
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative womenPeter B Gilbert, Jean-Louis Excler, Georgia D Tomaras, et al.
Hepatology (Baltimore, Md.)|October 21, 2015
Costs and consequences: Hepatitis C seroprevalence in the military and its impact on potential screening strategiesDavid M Brett-Major, Kevin D Frick, Jennifer A Malia, et al.
The New England Journal of Medicine|May 19, 2016
Prospective Study of Acute HIV-1 Infection in Adults in East Africa and ThailandMerlin L Robb, Leigh A Eller, Hannah Kibuuka, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 11, 2020
Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency VirusJoanna Hellmuth, Camilla Muccini, Donn J Colby, et al.
Plos Pathogens|December 16, 2014
Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activationAlexandra Schuetz, Claire Deleage, Irini Sereti, et al.
Pageof 112

Showing results (1001-1010 of 1,111) with videos related to

Sort By:
Pageof 112
Nature Medicine|June 13, 2018
Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infectionDonn J Colby, Lydie Trautmann, Suteeraporn Pinyakorn, et al.
Science Translational Medicine|December 15, 2017
Durability and correlates of vaccine protection against Zika virus in rhesus monkeysPeter Abbink, Rafael A Larocca, Kittipos Visitsunthorn, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 15, 2019
Terminal Effector CD8 T Cells Defined by an IKZF2<sup>+</sup>IL-7R<sup>-</sup> Transcriptional Signature Express FcγRIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular CytotoxicityProssy Naluyima, Kerri G Lal, Margaret C Costanzo, et al.
The Journal of Infectious Diseases|July 28, 2012
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/ESupachai Rerks-Ngarm, Robert M Paris, Supamit Chunsutthiwat, et al.
The Lancet. HIV|February 10, 2020
Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trialPunnee Pitisuttithum, Sorachai Nitayaphan, Suwat Chariyalertsak, et al.
Plos One|May 12, 2017
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative womenPeter B Gilbert, Jean-Louis Excler, Georgia D Tomaras, et al.
Hepatology (Baltimore, Md.)|October 21, 2015
Costs and consequences: Hepatitis C seroprevalence in the military and its impact on potential screening strategiesDavid M Brett-Major, Kevin D Frick, Jennifer A Malia, et al.
The New England Journal of Medicine|May 19, 2016
Prospective Study of Acute HIV-1 Infection in Adults in East Africa and ThailandMerlin L Robb, Leigh A Eller, Hannah Kibuuka, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 11, 2020
Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency VirusJoanna Hellmuth, Camilla Muccini, Donn J Colby, et al.
Plos Pathogens|December 16, 2014
Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activationAlexandra Schuetz, Claire Deleage, Irini Sereti, et al.
Pageof 112